Latest:
Managing Toxicities in Short- and Long-Term Treatment with ADCs
Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Matthew Davids, MD
Latest:
Dr. Davids Discusses Duvelisib Plus FCR in Young Patients With CLL
Matthew Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib plus fludarabine-cyclophosphamide-rituximab (FCR) as a frontline therapy for the treatment of younger patients with chronic lymphocytic leukemia.
Matthew E. Spector, MD
Latest:
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume Delineation
The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.
Matthew Farren, PhD
Latest:
Findings for Pembrolizumab Plus mFOLFOX6 in Advanced CRC
Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses findings from a multicenter, single-arm phase II clinical trial evaluating the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer (CRC).
Matthew Fowler
Latest:
PRO Data Support the Use of Pembrolizumab Combo in Persistent, Recurrent, or Metastatic Cervical Cancer
Patient-reported outcome data support a favorable benefit/risk profile for the combination of pembrolizumab plus chemotherapy, with or without bevacizumab, in patients with persistent, recurrent, or metastatic cervical cancer.
Matthew G. Mei, MD
Latest:
Dr. Mei on Investigational CAR T-Cell Therapies and Antibody-Drug Conjugates in Hodgkin Lymphoma
Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.
Matthew Gubens, MD
Latest:
Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC
Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.
Matthew H. Katz, MD
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer
An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Matthew J. Ellis, MD, PhD
Latest:
Dr. Ellis on Adjuvant CDK4/6 Inhibition in HR-Positive Breast Cancer
Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses adjuvant CDK4/6 inhibition in hormone receptor (HR)-positive breast cancer.
Matthew J. Matasar, MD
Latest:
Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL
A review of studies on safety management with CAR T-cell therapy, focusing on CRS/ICANS in the relapsed/refractory setting, key takeaways from Cohorts 4 and 6, and the impact of ZUMA-24 preliminary analysis on second-line safety strategies.